Hematopoietic stem cell transplantation from an infected SARS-CoV2 donor sibling.
Published in Bone marrow transplantation
Taxonomy.
Published in Bone marrow transplantation
COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma....
...Published in Bone marrow transplantation
COVID-19 outcomes in patients with hematologic disease
...Published in Bone Marrow Transplantation
Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile
...Published in Bone Marrow Transplantation
The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic c...
...Published in Bone Marrow Transplantation
The new coronavirus SARS-CoV-2 has rapidly spread over the world causing the disease by WHO called COVID-19. This pandemic poses unprecedented stress on the health care system including programs performing allogeneic and autologous hematopoietic cell transplantation (HCT) and cellular therapy such as with CAR T cells. Risk factors for severe diseas...
Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute ...
Published in Bone Marrow Transplantation
High rate of durable remissions post autologous stem cell transplantation for core-binding factor acute myeloid leukaemi...
...Published in Bone Marrow Transplantation
Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multipl...
...Published in Bone Marrow Transplantation
Despite the availability of several antiemetics, clinical findings show that control of chemotherapy-induced nausea and vomiting (CINV) continues to be a serious concern for hematological patients, mainly for those receiving multiple-day (MD) and high-dose (HD) chemotherapy (CT). For CINV prophylaxis, 5-hydroxytryptamine type-3 receptor antagonists...
Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide ...
...Published in Bone marrow transplantation
Post-transplant cyclophosphamide (PTCy) has become a promising option after allo-SCT, but infections may be more common than in traditional protocols. We herein report 117 consecutive adults who received PTCy-based alloSCT in our hospital: HaploSCT (34%), MRD (19%), and VUD (47%), respectively. The 18-month incidence of severe bacterial, viral, and...
